Table 1.
Patients’ characteristics
| All | Leiomyosarcoma | Carcinosarcoma | |
|---|---|---|---|
| N = 1635 | n = 566 | n = 1069 | |
| Age ≥ 60 years | 1028 (62.9) | 175 (30.9) | 1934 (79.8) |
| Race | |||
| White | 1162 (71.1) | 397 (70.1) | 765 (71.6) |
| Black | 324 (19.8) | 111 (19.4) | 214 (20.0) |
| Other a | 145 (8.9) | 56 (9.9) | 89 (8.3) |
| Unknown | 4 (0.2) | 3 (0.5) | 1 (0.1) |
| Year of diagnosis after 2009 | 1635 (100) | 566 (100.0) | 1069 (100.0) |
| AJCC Stage | |||
| Stage I | 1070 (65.4) | 443 (78.3) | 627 (58.7) |
| Stage II | 153 (9.4) | 66 (11.7) | 87 (8.1) |
| Stage III | 412 (25.2) | 57 (10.0) | 355 (33.2) |
| Grade | |||
| Grade 1 | 34 (2.1) | 21 (3.7) | 13 (1.2) |
| Grade 2 | 81 (5.0) | 53 (9.3) | 28 (2.6) |
| Grade 3 | 539 (33.0) | 91 (16.1) | 448 (41.9) |
| Undifferentiated/anaplastic | 380 (23.2) | 146 (25.8) | 234 (21.9) |
| Unknown | 601 (36.7) | 255 (45.1) | 346 (32.4) |
| Tumor size | |||
| ≤ 50 mm | 461 (28.2) | 87 (15.4) | 374 (35.0) |
| > 50 mm | 974 (59.6) | 424 (74.9) | 550 (51.5) |
| Unknown | 200 (12.2) | 55 (9.7) | 145 (13.5) |
| Lymphadenectomy | |||
| No | 583 (35.7) | 374 (66.1) | 209 (19.6) |
| Yes | 1025 (62.7) | 185 (32.7) | 840 (78.6) |
| Unknown | 27 (1.7) | 7 (1.2) | 20 (1.8) |
| Adjuvant radiation | |||
| No treatment | 1117 (68.3) | 476 (84.1) | 641 (60.0) |
| EBRT alone | 242 (14.8) | 64 (11.3) | 178 (16.7) |
| Brachytherapy alone | 159 (9.7) | 11 (1.9) | 148 (13.8) |
| Combination radiotherapy b | 95 (5.8) | 13 (2.3) | 82 (7.7) |
| Others | 22 (1.4) | 2 (0.4) | 20 (1.8) |
AJCC American Joint Committee on Cancer, EBRT external beam radiation therapy
Data are presented as number (percentage)
aIncluding American Indian, Alaska native, Asian Pacific Islander, and other unspecified
bCombination radiotherapy is EBRT with radioactive implants